(1,1-二丙基丁基)氯化铵 | 56065-37-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: (1,1-二丙基丁基)氯化铵
• 英文名称: 4-propylheptan-4-amine hydrochloride
• 英文别名: tri-n-propylmethylamine hydrochloride；1,1-Di-n-propyl-n-butylamine hydrochloride；4-propylheptan-4-amine;hydrochloride
• CAS: 56065-37-3
• 化学式: C₁₀H₂₃N*ClH
• 分子量: 193.76
• InChiKey: ZDHVFXADPHSDRI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.51
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  27.6
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1,1-二丙基丁基异氰酸酯 在 氢氧化钾 盐酸 作用下， 以 水 为溶剂， 以90%的产率得到(1,1-二丙基丁基)氯化铵
  参考文献：
  名称：

  Secondary amines

  摘要：

  甲基胺衍生物的公式为：##STR1##以及药学上可接受的酸加成盐，其中R.sub.1和R.sub.3各自代表一个氢原子或一个含有1至6个碳原子的直链或支链烷基、烯基或炔基自由基，R.sub.2代表一个含有2至7个碳原子的直链或支链烷基、烯基或炔基自由基，条件是当R.sub.2代表一个公式为CH.dbd.CH--R.sub.6的烯基自由基或一个公式为C.tbd.C--R.sub.6的炔基自由基时，其中R.sub.6代表一个氢原子或一个含有1至5个碳原子的直链或支链烷基自由基，R.sub.1和R.sub.3各自代表一个氢原子或一个烷基自由基，R.sub.4和R.sub.5相同或不同，各自代表一个氢原子，一个含有1至5个碳原子的直链或支链烷基、烯基或炔基自由基，或一个含有2至5个碳原子的ω-羟基烷基自由基，或者R.sub.4和R.sub.5共同代表一个含有2至6个碳原子的亚烷基自由基，一个含有1至5个碳原子的亚烷基自由基或自由基--CH.sub.2 --CH.sub.2 --O--CH.sub.2 --CH.sub.2 --，R.sub.1、R.sub.2和R.sub.3使得三取代甲基胺自由基最多含有13个碳原子。它们可用于治疗帕金森病，并用于纠正由神经阻滞剂引起的锥体外系扰动。

  公开号：

  US04201725A1

文献信息

• Active derivatives of methylamine in therapeutic compositions and
  申请人：Labaz

  公开号：US04057644A1

  公开（公告）日：1977-11-08

  Methylamine derivatives of the formula: ##STR1## and pharmaceutically acceptable acid addition salts thereof, wherein R.sub.1 and R.sub.3 each represent a hydrogen atom or a straight- or branched-chain alkyl, alkenyl or alkynyl radical containing from 1 to 6 carbon atoms, R.sub.2 represents a straight- or branched-chain alkyl, alkenyl or alkynyl radical containing from 2 to 7 carbon atoms with the proviso that when R.sub.2 represents an alkenyl radical of the formula CH.dbd.CH--R.sub.6 or an alkynyl radical of the formula C.tbd.C--R.sub.6, in which R.sub.6 represents a hydrogen atom or a straight- or branched-chain alkyl radical of 1 to 5 carbon atoms, R.sub.1 and R.sub.3 each represent an atom of hydrogen or an alkyl radical, R.sub.4 and R.sub.5, which are the same or different, each represent a hydrogen atom, a straight- or branched-chain alkyl, alkenyl or alkynyl radical containing from 1 to 5 carbon atoms or an .omega.-hydroxyalkyl radical containing from 2 to 5 carbon atoms or R.sub.4 and R.sub.5, when they are taken together represent an alkylene radical containing from 2 to 6 carbon atoms, an alkylidene radical containing from 1 to 5 carbon atoms or the radical --CH.sub.2 --CH.sub.2 --O--CH.sub.2 --CH.sub.2 --, R.sub.1, R.sub.2 and R.sub.3 being such that the trisubstituted methylamine radical possesses no more than 13 carbon atoms. They are useful for treating Parkinson's disease and for correcting extra-pyramidal disturbances provoked by neuroleptics.

  Methylamine derivatives of the formula: ##STR1## and pharmaceutically acceptable acid addition salts thereof, wherein R.sub.1 and R.sub.3 each represent a hydrogen atom or a straight- or branched-chain alkyl, alkenyl or alkynyl radical containing from 1 to 6 carbon atoms, R.sub.2 represents a straight- or branched-chain alkyl, alkenyl or alkynyl radical containing from 2 to 7 carbon atoms with the proviso that when R.sub.2 represents an alkenyl radical of the formula CH.dbd.CH--R.sub.6 or an alkynyl radical of the formula C.tbd.C--R.sub.6, in which R.sub.6 represents a hydrogen atom or a straight- or branched-chain alkyl radical of 1 to 5 carbon atoms, R.sub.1 and R.sub.3 each represent an atom of hydrogen or an alkyl radical, R.sub.4 and R.sub.5, which are the same or different, each represent a hydrogen atom, a straight- or branched-chain alkyl, alkenyl or alkynyl radical containing from 1 to 5 carbon atoms or an .omega.-hydroxyalkyl radical containing from 2 to 5 carbon atoms or R.sub.4 and R.sub.5, when they are taken together represent an alkylene radical containing from 2 to 6 carbon atoms, an alkylidene radical containing from 1 to 5 carbon atoms or the radical --CH.sub.2 --CH.sub.2 --O--CH.sub.2 --CH.sub.2 --, R.sub.1, R.sub.2 and R.sub.3 being such that the trisubstituted methylamine radical possesses no more than 13 carbon atoms. They are useful for treating Parkinson's disease and for correcting extra-pyramidal disturbances provoked by neuroleptics.
• Approaches to primary tert-alkyl amines as building blocks
  作者：Christina Tzitzoglaki、Antonios Drakopoulos、Athina Konstantinidi、Ioannis Stylianakis、Marianna Stampolaki、Antonios Kolocouris

  DOI：10.1016/j.tet.2019.06.016

  日期：2019.8

  Primary tert-alkyl amines include analogues of amantadine, a fragment commonly linked to pharmacophoric groups to enhance biological activity. The preparation of primary tert-alkyl amines is considered to be a difficult problem. Four synthetic procedures, some of which have been previously reported for the synthesis of amines with primary (RCH2NH2) or secondary (RR'CHNH2) alkyl and/or aryl groups,

  初级叔烷基胺包括金刚烷胺的类似物，通常连接到药效基团的片段，以提高生物活性。伯叔烷基胺的制备被认为是一个难题。四个合成步骤，其中一些已经用于与胺的合成已有报道初级（RCH 2 NH 2）或仲（RR'CHNH 2）烷基和/或芳基，伯合成进行了测试叔烷基胺（RR'R''CNH 2）包括金刚烷加合物在内的脂族系列。这些程序包括在形成和还原的叔烷基叠氮化物，在标准和改良条件Ritter反应，在加入有机金属试剂以ñ -叔丁基亚磺酰基酮亚胺和一锅在路易斯酸的存在下，Τi（IPRO）腈和有机金属试剂之间的反应4或CeCl 3.对于伯叔烷基胺，尚未开发这些合成途径。当前缺乏对伯叔烷基胺的合成路线的研究。研究了每种方法的反应条件和底物限制，第一种方法是最通用的方法，也适用于带有大分子加合物的化合物。
• Active derivatives of methylamine, therapeutic compositions containing
  申请人：Labaz

  公开号：US04026925A1

  公开（公告）日：1977-05-31

  Methylamine derivatives of the formula: ##STR1## and pharmaceutically acceptable acid addition salts thereof, wherein R.sub.1 and R.sub.3 each represent a hydrogen atom or a straight- or branched-chain alkyl, alkenyl or alkynyl radical containing from 1 to 6 carbon atoms, R.sub.2 represents a straight- or branched-chain alkyl, alkenyl or alkynyl radical containing from 2 to 7 carbon atoms with the proviso that when R.sub.2 represents an alkenyl radical of the formula CH=CH--R.sub.4 or an alkynyl radical of the formula C.tbd.C--R.sub.4, in which R.sub.4 represents a hydrogen atom or a straight- or branched-chain alkyl radical of 1 to 5 carbon atoms, R.sub.1 and R.sub.3 each represent an atom of hydrogen or an alkyl radical, R.sub.1, R.sub.2 and R.sub.3 being such that no compound of formula I possesses more than 13 carbon atoms. They are useful for treating Parkinson's disease and for correcting extra-pyramidal disturbances provoked by neuroleptics.

  甲基胺衍生物的化学式为：##STR1##及其药用可接受的酸盐，其中R.sub.1和R.sub.3分别表示氢原子或含有1至6个碳原子的直链或支链烷基、烯基或炔基基团，R.sub.2表示含有2至7个碳原子的直链或支链烷基、烯基或炔基基团，但当R.sub.2表示化学式CH=CH--R.sub.4的烯基基团或化学式C.tbd.C--R.sub.4的炔基基团时，其中R.sub.4表示氢原子或含有1至5个碳原子的直链或支链烷基基团，R.sub.1和R.sub.3各自表示氢原子或烷基基团，R.sub.1、R.sub.2和R.sub.3使得化合物I的碳原子数不超过13个。它们可用于治疗帕金森病和纠正由神经阻滞剂引起的额外锥体外运动障碍。
• METHOD FOR PREPARING AN IMPORTANT INTERMEDIATE OF LINAGLIPTIN
  申请人：2Y-CHEM, LTD.

  公开号：US20150274728A1

  公开（公告）日：2015-10-01

  The present invention discloses an improved process for preparing an important intermediate of linagliptin. In particular, disclosed are a process for preparing a compound V which is an important intermediate of linagliptin and has the structure V, and an industrial process of preparing linagliptin having excellent chemical and optical purities, which is an inhibitor of dipeptidyl peptidase-4 (DPP-IV), from the compound V. The process employs a phase-transfer catalyst, is high in yield, easy and simple to handle, environmentally friendly, suitable for industrial mass production, and can be implemented by a “one-pot process”.

  本发明公开了一种改进的制备利那格列汀重要中间体的工艺。具体公开了一种制备化合物V的工艺，该化合物V是利那格列汀的重要中间体，具有结构V，并且从化合物V中制备出具有优异化学和光学纯度的利那格列汀的工业工艺，利那格列汀是二肽基肽酶-4（DPP-IV）的抑制剂。该工艺采用相转移催化剂，产率高，易于操作和简单处理，环保，适合工业大规模生产，并且可以通过“一锅法”实施。
• Active derivatives of methylamino in therapeutic compositions and
  申请人：Labaz

  公开号：US04048334A1

  公开（公告）日：1977-09-13

  Methylamine derivatives of the formula: ##STR1## and pharmaceutically acceptable acid addition salts thereof, wherein R.sub.1 and R.sub.3 each represent a hydrogen atom or a straight- or branched-chain alkyl, alkenyl or alkynyl radical containing from 1 to 6 carbon atoms, R.sub.2 represents a straight- or branched-chain alkyl, alkenyl or alkynyl radical containing from 2 to 7 carbon atoms with the proviso that when R.sub.2 represents an alkenyl radical of the formula CH.tbd.CH--R.sub.4 or an alkynyl radical of the formula C=C--R.sub.4, in which R.sub.4 represents a hydrogen atom or a straight- or branched-chain alkyl radical of 1 to 5 carbon atoms, R.sub.1 and R.sub.3 each represent an atom of hydrogen or an alkyl radical, R.sub.1, R.sub.2 and R.sub.3 being such that no compound of formula I possesses more than 13 carbon atoms. They are useful for treating Parkinson's disease and for correcting extra-pyramidal disturbances provoked by neuroleptics.

  化学式为##STR1##的甲基胺衍生物及其药学上可接受的酸盐，其中R.sub.1和R.sub.3分别表示氢原子或含有1至6个碳原子的直链或支链烷基、烯基或炔基基团，R.sub.2表示含有2至7个碳原子的直链或支链烷基、烯基或炔基基团，但当R.sub.2表示公式CH.tbd.CH--R.sub.4的烯基基团或公式C=C--R.sub.4的炔基基团，其中R.sub.4表示氢原子或含有1至5个碳原子的直链或支链烷基基团时，R.sub.1和R.sub.3分别表示氢原子或烷基基团，R.sub.1、R.sub.2和R.sub.3的选择使得公式I的化合物中不含有超过13个碳原子。它们可用于治疗帕金森病并纠正由神经类药物引起的额外锥体外运动障碍。